One of the treatments for T2D involves inhibiting the dipeptidyl peptidase-IV (DPP4), which helps lower blood glucose levels while preserving the concentrations of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.